Trial
NCT02336048
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
B-Cell Chronic Lymphocytic Leukemia
Intervention
Chlorambucil
Why stopped
This study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of IRR.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-08